Evidence map›Paper›PMID 40378227›Full record

ArticleScience advances2025

Celluloepidemiology-A paradigm for quantifying infectious disease dynamics on a population level.

My K Ha, Anna Postovskaya, Maria Kuznetsova, Pieter Meysman, Vincent Van Deuren, Sabrina Van Ierssel, Hans De Reu, Jolien Schippers, Karin Peeters, Hajar Besbassi and 14 more

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

My K HaCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-6262-341X
Anna PostovskayaAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-0838-0728
Maria KuznetsovaCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-9834-9328
Pieter MeysmanAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-5903-633X
Vincent Van DeurenAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-7734-5547
Sabrina Van IersselDepartment of General Internal Medicine, Infectious Disease and Tropical Medicine, Antwerp University Hospital, Edegem, Belgium.ORCID 0000-0003-2955-4130
Hans De ReuLaboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0003-0120-3160
Jolien SchippersCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
Karin PeetersCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
Hajar BesbassiCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.
Leo HeyndrickxVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-5862-7821
Betty WillemsVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Joachim MariënDepartment of Ecology and Evolutionary Biology, University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-7023-445X
Esther BartholomeusAntwerp Center for Translational Immunology and Virology (ACTIV), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0003-2127-5161
Koen VercauterenClinical Virology Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0003-1472-9938
Philippe BeutelsCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0001-5034-3595
Pierre Van DammeAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-8642-1249
Eva LionAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-2420-0301
Erika VliegheDepartment of General Internal Medicine, Infectious Disease and Tropical Medicine, Antwerp University Hospital, Edegem, Belgium.ORCID 0000-0002-4865-3030
Kris LaukensAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-8217-2564
Samuel CoenenLaboratory of Medical Microbiology (LMM), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-1238-8052
Reinout NaesensDepartment of Clinical Biology, Antwerp Hospital Network, Antwerp, Belgium.ORCID 0000-0003-1004-7737
Kevin K AriënVirology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Benson OgunjimiCenter for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium.ORCID 0000-0002-0831-2063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To complement serology as a tool in public health interventions, we introduced the "celluloepidemiology" paradigm where we leveraged pathogen-specific T cell responses at a population level to advance our epidemiological understanding of infectious diseases, using SARS-CoV-2 as a model. Applying flow cytometry and machine learning on data from more than 500 individuals, we showed that the number of T cells with positive expression of functional markers not only could distinguish patients who recovered from COVID-19 from controls and pre-COVID donors but also identify previously unrecognized asymptomatic patients from mild, moderate, and severe recovered patients. The celluloepidemiology approach was uniquely capable to differentiate health care worker groups with different SARS-CoV-2 exposures from each other. T cell receptor (TCR) profiling strengthened our analysis by revealing that SARS-CoV-2-specific TCRs were more abundant in patients than in controls. We believe that adding data on T cell reactivity will complement serology and augment the value of infection morbidity modeling for populations.

Indexed as

Communicable DiseasesCOVID-19SARS-CoV-2Flow CytometryHumansMachine LearningReceptors, Antigen, T-CellT-LymphocytesReceptors, Antigen, T-Cell

Identifiers

PMID40378227
PMCPMC12083542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.